ABCM Stock Overview
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Abcam plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.99 |
| 52 Week High | US$25.32 |
| 52 Week Low | US$12.48 |
| Beta | 0.86 |
| 11 Month Change | 3.41% |
| 3 Month Change | 4.90% |
| 1 Year Change | 54.67% |
| 33 Year Change | 27.07% |
| 5 Year Change | n/a |
| Change since IPO | 21.47% |
Recent News & Updates
Shareholder Returns
| ABCM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.08% | -6.5% | -1.0% |
| 1Y | 54.7% | 14.6% | 30.3% |
Return vs Industry: ABCM exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: ABCM exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| ABCM volatility | |
|---|---|
| ABCM Average Weekly Movement | 1.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABCM has not had significant price volatility in the past 3 months.
Volatility Over Time: ABCM's weekly volatility has decreased from 7% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,760 | Alan Hirzel | www.abcam.com |
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company’s principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies.
Abcam plc Fundamentals Summary
| ABCM fundamental statistics | |
|---|---|
| Market cap | US$5.52b |
| Earnings (TTM) | US$3.14m |
| Revenue (TTM) | US$476.75m |
1,759x
P/E Ratio11.6x
P/S RatioIs ABCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABCM income statement (TTM) | |
|---|---|
| Revenue | UK£379.70m |
| Cost of Revenue | UK£91.60m |
| Gross Profit | UK£288.10m |
| Other Expenses | UK£285.60m |
| Earnings | UK£2.50m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.011 |
| Gross Margin | 75.88% |
| Net Profit Margin | 0.66% |
| Debt/Equity Ratio | 16.4% |
How did ABCM perform over the long term?
See historical performance and comparison